Antihyperuricemic Effect of Urolithin A in Cultured Hepatocytes and Model Mice

Molecules. 2020 Nov 4;25(21):5136. doi: 10.3390/molecules25215136.

Abstract

Hyperuricemia is defined as a disease with high uric acid (UA) levels in the blood and a strong risk factor for gout. Urolithin A (UroA) is a main microbial metabolite derived from ellagic acid (EA), which occurs in strawberries and pomegranates. In this study, we evaluated antihyperuricemic effect of UroA in both cultured hepatocytes and hyperuricemic model mice. In cultured hepatocytes, UroA significantly and dose-dependently reduced UA production. In model mice with purine bodies-induced hyperuricemia, oral administration of UroA significantly inhibited the increase in plasma UA levels and hepatic xanthine oxidase (XO) activity. In addition, DNA microarray results exhibited that UroA, as well as allopurinol, a strong XO inhibitor, induced downregulation of the expression of genes associated with hepatic purine metabolism. Thus, hypouricemic effect of UroA could be, at least partly, attributed to inhibition of purine metabolism and UA production by suppressing XO activity in the liver. These results indicate UroA possesses a potent antihyperuricemic effect and it could be a potential candidate for a molecule capable of preventing and improving hyperuricemia and gout.

Keywords: AML12 hepatocyte; ellagic acid; hyperuricemia; uric acid; urolithin A.

MeSH terms

  • Animals
  • Cell Line
  • Coumarins / pharmacology*
  • Disease Models, Animal
  • Gout Suppressants / pharmacology*
  • Hepatocytes / metabolism*
  • Hyperuricemia* / blood
  • Hyperuricemia* / drug therapy
  • Liver / metabolism*
  • Male
  • Mice
  • Mice, Inbred ICR
  • Uric Acid / metabolism*

Substances

  • Coumarins
  • Gout Suppressants
  • 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one
  • Uric Acid